Inovio has a great deal of funding at its back and is one of the first companies conducting clinical trials in the U.S. In addition to this company's strong fundamental backing, it is also up 133% in the last 3 months and both indicators are in agreement showing oversold levels - a clear buy signal. This stock is one to watch as it approaches old highs.